Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 96

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 96
---
, to explore a sale of Enfusion or another strategic alternative to remaining a standalone company.
The Special Committee directed representatives of Goldman Sachs to promptly prepare an analysis to assist the Special Committee in its review of all strategic alternatives, including whether it was the right time to explore a sale of Enfusion or
another strategic alternative.

Later on September 23, 2024, the Special Committee formally engaged Goldman Sachs as the
financial advisor to the Special Committee.

On September 27, 2024, the Special Committee held a meeting with representatives of
Dechert and Goldman Sachs in attendance. Representatives of Goldman Sachs briefed the Special Committee on their work to assist the Special Committee in its review with Enfusion management of the preliminary long-range plan and projections that
Enfusion management had prepared for Enfusion. The Special Committee provided representatives of Goldman Sachs with feedback to relay to management regarding the long-range plan and projections for Enfusion. Representatives of Goldman Sachs updated
the Special Committee on unsolicited and general inbound communications of interest from parties potentially interested in pursuing a transaction with Enfusion.

On October 4, 2024, the Special Committee held a meeting with representatives of Dechert in attendance. Representatives of Dechert
reviewed certain considerations that could be relevant to the Special Committee’s review of all strategic alternatives, including considerations relating to their fiduciary duties to Enfusion and Enfusion Stockholders. Representatives of
Goldman Sachs then joined the meeting and briefed the Special Committee on their work to assist the Special Committee in its review of all strategic alternatives. The Special Committee also reviewed the preliminary long-range plan and projections
for Enfusion that had been prepared by Enfusion management and discussed the assumptions underlying that plan. The Special Committee provided representatives of Goldman Sachs with feedback to relay to management regarding the long-range plan and
projections for Enfusion. Representatives of Goldman Sachs updated the Special Committee on inbound indications of interest from parties potentially interested in pursuing a transaction with Enfusion.

On October 11, 2024, the Special Committee held a meeting with representatives of Dechert and Goldman Sachs in attendance.
Representatives of Goldman Sachs shared their views as to Enfusion’s strategic alternatives, including whether it was the right time to explore a sale of Enfusion or another strategic alternative to the standalone plan. Representatives of
Goldman Sachs also shared their preliminary financial analysis perspectives. The Special Committee reviewed the preliminary long-range plan and projections for Enfusion that had been prepared by Enfusion management and discussed the assumptions
underlying that plan. Representatives of